Inhibition of cholesterol biosynthesis overcomes enzalutamide resistance in castration-resistant prostate cancer (CRPC)

Enzalutamide, a nonsteroidal second-generation antiandrogen, has been recently approved for the management of castration-resistant prostate cancer (CRPC). Although patients can benefit from enzalutamide at the beginning of this therapy, acquired enzalutamide resistance usually occurs within a short...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:J Biol Chem
Hauptverfasser: Kong, Yifan, Cheng, Lijun, Mao, Fengyi, Zhang, Zhuangzhuang, Zhang, Yanquan, Farah, Elia, Bosler, Jacob, Bai, Yunfeng, Ahmad, Nihal, Kuang, Shihuan, Li, Lang, Liu, Xiaoqi
Format: Artigo
Sprache:Inglês
Veröffentlicht: American Society for Biochemistry and Molecular Biology 2018
Schlagworte:
Cell Biology
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6139550/
https://ncbi.nlm.nih.gov/pubmed/30089652
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1074/jbc.RA118.004442
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge